Please login to the form below

Not currently logged in
Email:
Password:

IGAS

This page shows the latest IGAS news and features for those working in and with pharma, biotech and healthcare.

Novartis shares positive phase 3 results for atrasentan in rare kidney disease

Novartis shares positive phase 3 results for atrasentan in rare kidney disease

Novartis has shared positive results from a late-stage trial of its experimental drug atrasentan in patients with IgA nephropathy (IgAN), a rare kidney disease. ... Affecting approximately 110, 000 people in the US, IgAN occurs when IgA accumulates in

Latest news

More from news
Approximately 2 fully matching, plus 18 partially matching documents found.

Latest appointments

  • New hires at Nanoform, Leo Pharma and Calliditas New hires at Nanoform, Leo Pharma and Calliditas

    IgA nephropathy (IgAN) – also known as Berger’s disease. ... Currently, there are no approved treatments for IgA Nephropathy, and Nefecon has the potential to be a disease-modifying treatment for patients suffering from this chronic autoimmune disease

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

PMHub

Add my company
Bedrock Healthcare Communications

Bedrock Healthcare Communications is an award-winning, independent agency founded in 2011. We partner with healthcare professionals, patients, and global pharmaceutical...

Latest intelligence

The evolving healthcare advertising landscape
Industry experts share their insights on the emerging trends in healthcare advertising...
Clinical trial considerations: Why supporting HCPs matters...
When HCPs have the necessary information, they can more easily communicate it to patients using simplified language and a confident, calm tone....
Six ways to provide successful e-learning programs to healthcare professionals
Practical tips to setting up high-impact e-learning programs...